Evidence map›Paper›PMID 35152800›Full record

ArticleAnnals of medicine2022

Apigenin exerts protective effect and restores ovarian function in dehydroepiandrosterone induced polycystic ovary syndrome rats: a biochemical and histological analysis.

Fangxin Peng, Yichuan Hu, Shu Peng, Ni Zeng, Lei Shi

Open access · goldAbstract read
In one paragraph

Article in Annals of medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Apigenin Prevents Ovarian Aging by Regulating CaAntioxidants (Basel, Switzerland) · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Liraglutide Improves PCOS Symptoms in Rats by Targeting FDX1.Reproductive sciences (Thousand Oaks, Calif.) · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Fangxin PengDepartment of Reproductive Medicine, Maternal and Child Health Hospital of HuBei Province, Hubei, China.
Yichuan HuDepartment of Anaesthesiology, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China.
Shu PengDepartment of Reproductive Medicine, Maternal and Child Health Hospital of HuBei Province, Hubei, China.
Ni ZengDepartment of Reproductive Medicine, Maternal and Child Health Hospital of HuBei Province, Hubei, China.
Lei ShiDepartment of Reproductive Medicine, Maternal and Child Health Hospital of HuBei Province, Hubei, China.
Hubei Provincial Women and Children's Hospital · CNWuhan Union Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPolycystic ovarian syndrome (PCOS) is one of the major causes encouraging the elevation of androgens, obesity along with menstrual complications. Here we study the effect of Apigenin in rat model of polycystic ovarian syndrome.

methodsFemale Sprague Dawley (SD) rats were treated with Dehydroepiandrosterone (DHEA) (6 mg/100g) opting the post-pubertal approach for developing rat model of polycystic ovarian syndrome, Metformin was used as standard. The treatments were given for 21 days along with coloproctological analysis. After the treatment regimen, the biochemical analysis was carried in plasma samples, whereas the ovaries were submitted for histopathological analysis.

resultsThe treatment of DHEA resulted in disturbed lipid profile and anti-oxidant status along with increased weight, ovarian diameter and cysts in rats confirming the development of PCOS. However, treatment of Apigenin showed ameliorative effect by improving the lipid profile and anti-oxidant status, the treatment also normalised the body weight, reduced ovarian diameter, cysts and restored the healthy follicles compared to control rats. The treatment of Apigenin also suppressed the levels of oestradiol and testosterone compared to control group, also, levels of progesterone were increased in Apigenin treated group of rats. The treatment of Apigenin suppressed the levels of inflammatory cytokines TNF-α and IL-6. It was observed that the effect of Apigenin were to some extent parallel to standard drug Metformin.

conclusionThe findings confirmed that Apigenin ameliorates the disturbed hormonal levels, lipid profile and antioxidant status in PCOS rats.

Indexed as

Polycystic Ovary SyndromeAnimalsApigeninDehydroepiandrosteroneDisease Models, AnimalFemaleHumansRatsRats, Sprague-DawleyApigeninDehydroepiandrosteroneanti-oxidantApigeninlipid profilepolycystic ovarian syndrome

Identifiers

PMID35152800
PMCPMC8843206
OpenAlexW4211103232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.